Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Noom will offer its version of compounded semaglutide - the active ingredient in Wegovy and diabetes drug Ozempic - as part ... U.S. Food and Drug Administration regulations.

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight ... dosages slightly different from the standard, FDA-approved amounts or including additives such as vitamins ...